Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Pharmaessentia Corporation is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. MARVICH, MARIA is the busiest examiner, with 1 pending office action currently under review. The distribution of 2 pending actions among 2 distinct examiners and 2 distinct art units means each case is being handled in a different technical environment.
The busiest examiner pending count of 1 shows that no single examiner is managing more than one case for the company. This structure indicates a range of focuses within the biotechnology sector. Each of the 2 distinct examiners handles a single action, providing a variety of perspectives on the company's technology. The presence of 2 distinct art units suggests that the biotechnology filings cover multiple technical sections of the patent office. This arrangement requires the company to manage interactions with 2 different examiners across 2 separate art units. MARVICH, MARIA is one of the 2 distinct examiners handling the pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 46d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 46d |
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19361525 | Unique Interferon Alpha 2B And New Method Of Making Thereof | MARVICH, MARIA | 1634 | §102§112 | Non-Final OA | — | Pending | Oct 17, 2025 |
| 18883789 | METHOD TO INCREASE DRUG SUBSTANCE YIELD | BOWERS, ERIN M | 1653 | §103§112 | Final Rejection | 46d | Pending | Sep 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial